Investing

Eastman Kodak Company KODK Stock News

Eastman Kodak Company (NYSE: KODK) is having an overwhelmingly strong start to the trading session this morning, and for good reason. In a press release issued late yesterday, the company announced an entrance into the blockchain. Today, we’ll talk about the news, what we’re seeing from the stock, and what we’ll be watching for with regard to KODK ahead.





KODK Climbs On Blockchain News

As mentioned above, Eastman Kodak Company is having an overwhelmingly strong start to the trading session this morning after announcing an entrance into the blockchain with its own cryptocurrency. In the release, KODK announced the launch of the KODAKOne image rights management platform as well as KODAKCoin. These products are being launched through a partnership that KODK entered into with WENN Digital.




KODK said that, through the use of blockchain technology, the KODAKOne platform will create an encrypted, digital ledger focused on right of ownership for photographers to register both new and archived work. From there, this work can be licensed through the platform.

The KODAKOne platform will run on KODAKCoin, a cryptocurrency the company has created to assist photographers in receiving payment for their work immediately upon sale. Of course, KODK explained that these sales would take place securely through their blockchain platform. In a statement, Jeff Clarke, CEO at KODK, had the following to offer:

“For man in the tech industry, ‘blockchain’ and ‘cryptocurrency’ are hot buzzwords, but for photographers who’ve long struggled to assert control over their work and how it’s used, these buzzwords are the keys to solving what felt like an unsolvable problem… Kodak has always sought to democratize photography and make licensing fair to artists. These technologies give the photography community an innovative and easy way to do just that.”

What We’re Seeing From The Stock As A Result

As investors, one of the first things that we learn is that the news moves the market. Recently, there have been few stories in the news that cause movement quite like what we see when a publicly-traded company mentions the blockchain. Just take a look at DPW, LFIN, OTIV, and INPX, and what happened when they announced an entrance into the blockchain. So, it’s no surprise that with Eastman Kodak Company announcing an entrance into the crypto-world themselves, we’re seeing strong gains in the value of the stock. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (8:39), KODK is trading at $11.25 per share after a gain of $4.45 per share (65.4%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on KODK. In particular, we’re interested in following the story surrounding the company’s entrance into the blockchain and excited to learn more about how this will help the photography community as a whole. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Riot Blockchain Inc RIOT Stock News

Riot Blockchain Inc (NASDAQ: RIOT) is having a strong day in the market today, and for good reason. The company announced the establishment of a new subsidiary, leading to excitement among investors and sending the stock toward the top. Today, we’ll talk about the new subsidiary, what we’re seeing from the stock, and what we’ll be watching for with regard to RIOT ahead.





RIOT Gains On Establishment Of Subsidiary

As mentioned above, Riot Blockchain is having a strong day in the market today after issuing a press release announcing the establishment of a subsidiary. Early this morning, the company announced that it has established Digital Green Energy Corp as a wholly-owned subsidiary.




In the release, RIOT said that the purpose of the company is to explore international infrastructure opportunities. Ultimately, the company intends to identify environmentally friendly projects with large energy capacity and a cost-efficient rate for cryptocurrency mining and data center operations.

RIOT also said that Daniel Stefan Robertsen has been appointed as President of the new subsidiary. Mr. Robertsen will begin his role in the company on January 24, 2018. In a statement, John O’Rourke, Chairman and CEO of RIOT, had the following to offer:

“We believe green energy infrastructure will continue to be in strong demand and we aim to position Riot accordingly… Securing access to a meaningful amount of reliable energy at a low cost will be Digital Green Energy’s focus moving forward. Mr. Robertsen has expertise building and managing data center operations for companies including Facebook and Bitfury. He will be instrumental in building and expanding our energy infrastructure for efficient cryptocurrency mining and data center operations.”

What We’re Seeing From The Stock

At the end of the day, we know that the news moves the market, and the news of a new subsidiary that could become a strong revenue stream is definitely positive. As a result, we’re seeing strong movement in the value of Riot Blockchain today. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (12:20), RIOT is trading at $24.84 per share after a gain of $1.42 per share (6.06%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on RIOT. In particular, we’re interested in following the story surrounding the new subsidiary and excited to learn more about what the company will be doing. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Altice USA Inc ATUS Stock News

Altice USA Inc (NYSE: ATUS) is having an overwhelmingly strong day in the market today, and for good reason. The company announced spinoff plans that led to excitement among investors, sending the stock soaring. Today, we’ll talk about the plans, what we’re seeing from ATUS, and what we’ll be watching for ahead.





ATUS Gains On Spinoff Plans

As mentioned above, Altice USA is having an overwhelmingly strong day in the market today after the company’s parent company, Altice N.V., announced a spinoff. The company announced that its Board of Directors has approved plans for the separation of Altice USA Inc. from Altice NV.

In the PR, ATUS said that the spinoff will give each business a better opportunity to focus more on the distinct opportunities in their respective markets. The move also increases transparency for investors. In the release, the company said that the spinoff is planned to be completed by the end of the second quarter of 2018. Of course, the move is still subject to regulatory and shareholder approvals. In a statement, Patrick Drahi, founder of ATUS, had the following to offer:




“The separation will allow both Altice Europe and Altice USA to focus on their respective operations and execute against their strategies, deliver value for shareholders, and realize their full potential. Both operations will have the fundamental Altice Model at their heart through my close personal involvement as well as that of the historic founding team.

Altice Europe has tremendous opportunities as we deliver on our operation aspirations around much improved customer service and monetizing our premium infrastructure and content assets. Altice Europe has a unique asset base that is fully converged and fiber rich with strong number one or number two positions in each market with nationwide fixed and mobile coverage. At the core of our strategy is the operation and financial turnaround in France and Portugal. In parallel, we have a clear plan to further strengthen our long-term balance sheet position as we execute our non-core asset disposals.

Altice USA sees exciting opportunities in the US market as we start 2018 with strong momentum. We have a full operational agenda to deliver best-in-class services to our customers, drive innovation and advance our fiber investment strategy. The new organization structure will enable us to focus even more on executing this agenda while enhancing transparency for our investors. We remain confident in achieving the objectives we set out at the beginning of our journey in the US and affirm the efficiency targets set out at the time of the acquisitions of Suddenlink and Optimum.”

What We’re Seeing From The Stock As A Result

One of the first things that we learn when we start to dabble in the market is that the news causes movement. In this particular case, investors are loving the idea of the spinoff, which can be seen through the gains in the value of the stock. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:12), ATUS is trading at $24.19 per share after a gain of $3.10 per share or 14.70% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ATUS. In particular, we’re interested in following the story surrounding the spinoff as it is still subject to regulatory and shareholder approval. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 850
Pain Therapeutics Inc PTIE Stock News

Pain Therapeutics, Inc. (NASDAQ: PTIE) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced overwhelmingly positive data surrounding a key clinical candidate, leading to excitement among investors and sending the stock screaming for the top. Today, we’ll talk about the results, what we’re seeing from PTIE, and what we’ll be watching for ahead.





PTIE Gains On Positive Results

As mentioned above, Pain Therapeutics is having an overwhelmingly strong day in the market today after reporting positive clinical results. In a press release issued early this morning, the company announced positive top-line results from a human abuse potential study of REMOXY, a late-stage drug candidate.

In the press release, PTIE said that study results indicate that nasal administration of REMOXY resulted in significantly lower abuse potential in non-dependent, recreational opioid users compared to immediate-release oxycodone.




In the release, PTIE said that all study subjects reported reduced ‘Drug Liking,’ ‘Take Drug Again,’ and ‘Drug High’ for REMOXY when compared to oxycodone IR. Also, the company said that nasal administration of REMOXY showed lower exposure to oxycodone, lower peak concentrations, and longer time to peak drug concentration against comparator drugs. All of this leads to a lower rate of abuse potential. In a statement, Remi Barbier, President and CEO at Pain Therapeutics, had the following to offer:

“We believe these data indicate REMOXY may have limited nasal abuse potential relative to comparator drugs… We have now successfully completed all studies necessary to submit the REMOXY NDA to the FDA, and plan to do so shortly.”

What We’re Seeing From The Stock

As investors, one of the first things that we learn is that the news moves the market. In this particular, case, study results proved to be overwhelmingly positive. So naturally, investors are becoming overwhelmingly excited and pushing the stock toward the top. Currently (10:35), PTIE is trading at $11.72 per share after a gain of $7.50 per share (177.73%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahed

Moving forward, the CNA Finance team will continue to keep a close eye on PTIE. In particular, we’re interested in following the company through the process, now that the data is believed to be strong enough for NDA submission. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1114
InspireMD Inc NSPR Stock News

InspireMD Inc (NYSEAMERICAN: NSPR) is having an overwhelmingly positive start to the trading session this morning, and for good reason. The company announced that it will host a conference call, and gave some pretty exciting hints as to what will be discussed. Today, we’ll talk about the call, what we’re seeing from the stock, and what we’ll be watching for with regard to NSPR ahead.





NSPR Gains On Conference Call Announcement

As mentioned above, InspireMD is having an overwhelmingly positive start to the trading session this morning after announcing that it will host a conference call tomorrow, January 10th. The call will be held at 10:00 a.m. Eastern Time and will be focused on recent developments, preliminary unaudited fourth quarter 2017 sales results, and proposals under consideration for the upcoming shareholder meeting.




If you would like to join the NSPR conference call, US callers can dial in toll free at (877) 407-0782 or international callers can call locally to (201) 689-8567. NSPR said it will also be archiving a webcast on the company’s website as well as a telephone replay of the call, which will be available about one hour after the close of the call.

What We’re Seeing From The Stock

One of the first things that we learn when we start to dabble in the market is that the news causes movement. With coming information, it only makes sense that we’re seeing gains in the value of InspireMD today. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:20), NSPR is trading at $0.27 per share after a gain of $0.07 per share (32.62%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NSPR. In particular, we’re interested in following the conference call and excited to learn about the developments that will be announced. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Inpixon INPX Stock News

Inpixon (NASDAQ: INPX) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced news surrounding its entrance into the blockchain, leading to excitement among investors and sending the stock soaring. Today, we’ll talk about the news, what we’re seeing from the stock, and what we’ll be watching for with regard to INPX ahead.





INPX Gains On Blockchain News

As mentioned above, Inpixon is having an incredibly strong start to the trading session this morning after announcing blockchain news. In a press release issued early this morning, the company said that it will use blockchain technology to develop a global repository of device reputations to help enterprise security and retailers mitigate rogue-device risk proactively.




In the press release, INPX said that it believes that blockchain, in connection with its Indoor Positioning Analytics platform, will help to drive down the overall risk for retailers. Ultimately, the risk is reduced by creating a self-managing payment platform that will deliver value and reward its customers for loyalty, while also reducing threat by leveraging device reputation through account management.

INPX said that it can rapidly identify and quarantine mal-devices with blockchain technology, which will help to prevent fraudulent transactions, creating the potential to protect millions of dollars. In a statement, Nadir Ali, CEO of INPX, had the following to offer:

“The use of blockchain technology is one of several strategic product development plans we have for 2018 that we believe will modernize Indoor Positioning radically… With the use of blockchain technologies for various applications, including security enforcement, payment authorization, identity verification, and access authentication, the Inpixon IPA platform which provides accurate indoor positioning context for millions of devices will be able to offer unique device reputation.”

How The Stock Reacted To The News

As investors, one of the first things that we learn is that the news causes movement. Recently, there have been few bits of news that cause quite as much movement as blockchain news. Just take a look at what we saw from LFIN, DPW, OTIV, and others when they announced their entrance into the world of blockchain. Considering this, with the news from Inpixon that it is making an entrance into the blockchain as well, it only makes sense that we’re seeing strong gains. At the moment (10:00), INPX is trading at $0.35 per share after a gain of $0.13 per share (56.76%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on INPX. In particular, we’re interested in watching the company’s transformation as it adds blockchain technology into its mix of strong products. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Yield10 Bioscience Inc YTEN Stock News

Yield10 Bioscience Inc (NASDAQ: YTEN) is having an overwhelmingly strong start to the trading session in the pre-market hours this morning, and for good reason. The company reported encouraging results from key field tests. Today, we’ll talk about the results, what we’re seeing from the stock, and what we’ll be watching for with regard to YTEN ahead.





YTEN Gains On Encouraging Results

As mentioned above Yield10 Bioscience is having a strong start to the trading session this morning after reporting encouraging results from Field Tests. In a press release issued early this morning, the company offered test results of its novel yield trait gene C3003 in Camelina and canola.

YTEN is a company that’s focused on building better plants through proprietary, breakthrough technologies that produce higher yields in major food and feed crops with the goal of enhancing global food security with lower inputs of land, water and fertilizer.




The field tests were conducted in two sites in Canada with the main objectives being to evaluate the performance of the novel yield trait gene C3003. The results showed an improvement in seed yields. In a statement, Kristi Snell, Ph.D., Chief Science Officer at YTEN, had the following to offer:

“In the results of our field tests, we are pleased to see that the yield characteristics we’ve observed for C3003 in Camilina are translating quite predictably into canola… Combining our metabolic modeling of the trait with the results of our field tests, we are continuing to learn more about the C3003 trait that may enable us to develop methods to further optimize improvements in seed yield. In our field tests in Camelina, we evaluated two seed specific promoters, one in replicated field plots and one in smaller scale seed bulk up experiments, and both show promise for driving performance of the C3003 trait in Camelina. In our field tests planned for spring 2018, we look forward to evaluating our newer second generation C3003 promoter that produced promising seed yield results during seed bulk up.”

What We’re Seeing From The Stock

As investors, one of the first things that we learn is that the news moves the market. Any time positive news is released by a publicly traded company, we can expect to see gains in the value of the stock that’s representative of the company. That’s exactly what we’re seeing out of Yield10 Bioscience today. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:41), YTEN is trading at $1.74 per share after a gain of $0.06 per share or 3.57% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on YTEN. In particular, we’re interested in following the story surrounding the C3003 trait and excited to learn about future results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 497
Biocept, Inc. BIOC Stock News

Biocept Inc (NASDAQ: BIOC) is having an incredibly strong start to the trading session in the pre-market hours this morning, and for good reason. The company announced new with regard to study data that’s leading to excitement among investors. Today, we’ll talk about that news, what we’re seeing from the stock, and what we’ll be watching with regard to BIOC ahead.





BIOC Announces Positive Data

As mentioned above, Biocept is having an overwhelmingly strong start to the trading session in the pre-market hours after releasing data. Early this morning, the company issued a press release surrounding recently acquired data.

In the release, the company announced that incorporation of the Thermo Fisher QuantStudio5, also known as QS5, real-time PCR instrument into their Target SelectorTM ctDNA lung cancer assays improves the detection of key lung cancer mutations. BIOC said that data from 3,000 samples were analyzed through the use of the company’s liquid biopsy assays for EGFR, BRAF and KRAS mutations, it was able to demonstrate single mutant copy detections on the QS5 platform with more than 99% sensitivity and more than 99% specificity.




In the release, BIOC said that it plans on presenting the full results in a poster at the Fift AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic. The event will be held from January 8th to 11th in San Diego. In a statement, Veena Singh, MD, Vice President and Senior Medical Dirctor at Biocept had the following to offer:

“These results demonstrate that the high sensitivity of our Target SelectorTM ctDNA assay platform is further improved by the use of QS5 versus the PCR instrument we previously used…. The ability to rapidly and accurately assess the molecular status of a patient’s tumor using a simple blood draw can be a critical factor in the selection of individualized targeted therapy. Our tests can further provide for the monitoring of response to therapy over time without invasive tissue biopsies that can be difficult to perform in patients diagnosed with cancer.”

The above statement was followed up by Michael Nall, CEO and President at BIOC. Here’s what he had to offer:

“We are very pleased to showcase the superb performance of our Targeted SelectorTM ctDNA assays using the QS5 at this conference attended by professionals directly involved in the care of patients with lung cancer… We believe that these results further solidify our leadership position in the liquid biopsy segment and are representative our our actions to build the body of evidence supporting the analytical performance and clinical utility of our proprietary liquid biopsy tests.”

What We’re Seeing From The Stock

One of the first things that we learn when we start to dabble in the market is that the news causes movement. In this particular case, the news surrounding Biocept proved to be overwhelmingly positive, leading to excitement surrounding the stock and the strong gains that we’re seeing at the moment. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:18), BIOC is trading at $0.75 per share after a gain of $0.03 per share or 4.87% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on BIOC. In particular, we’re interested in following the ongoing development and continued work surrounding the company’s various liquid biopsy tests. Nonetheless, we’ll continue to follow the story closely and bring the story to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 506
Genetic Technologies Limited (ADR) GENE Stock News

Genetic Technologies Limited (ADR) (NASDAQ: GENE) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced news it received from the NASDAQ, which proved to be a source of excitement for investors. Today, we’ll talk about the news, what we’re seeing from the stock, and what we’ll be watching for with regard to GENE ahead.





GENE Gains On NASDAQ Compliance

As mentioned above, Genetic Technologies is having an incredibly strong start to the trading session today after announcing news that it has received from the NASDAQ. In a press release issued early this morning, GENE announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market.

The letter, received on January 8th, informed the company that the minimum closing bid price per share was $1.00 or above for a period of 10 consecutive trading sessions from December 20, 2017 to January 4, 2018. As a result of this, GENE has regained compliance with Nasdaq Marketplace Listing Rule 5550(a)(2). As a result of regaining compliance, the Nasdaq Listing Rules deficiency notice, dated July 19, 2017, has been remedied and the matter is now closed.




What We’re Seeing From The Stock As A Result

As investors, one of the first things that we learn when we start to dabble in the market is that the news causes moves. In this particular case, the news of Genetic Technologies regaining compliance proved to be overwhelmingly positive, leading to excitement among investors and sending the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:05), GENE is trading at $1.42 per share after a gain of $0.18 per share (14.52%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on GENE. In particular, we’re interested in following the company’s ongoing development of its relatively strong pipeline of product candidates, as well as watching the stock price to ensure that the stock maintains NASDAQ compliance. Nonetheless, we’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Helios and Matheson Analytics Inc HMNY Stock News

Helios and Matheson Analytics Inc (NASDAQ: HMNY) is having an incredibly strong start to the trading session in the pre-market hours this morning, and for good reason. The company announced news with regard to subscriber growth that’s leading to excitement among investors. Today, we’ll talk about the news, what we’re seeing from the stock, and what we’ll be watching for with regard to HMNY ahead.





HMNY Gains On Subscriber Growth

As mentioned above, Helios and Matheson Analytics is having an incredibly strong start in the pre-market hours today, and for good reason. The company announced subscriber growth that is happening at a rapid rate. In fact, in a press release issued early this morning, the company said that its subscriber base has increased to 1.5 million subscribers. That’s incredible news considering the fact that HMNY just announced that it reached 1 million subscribers about a month ago. In a statement, Ted Farnsworth, Chairman and CEO at HMNY, had the following to offer:




“MoviePassTM is attracting people back to the movie theaters by lowering their cost, which we believe is transformational for the industry… We believe the data MoviePass collects from these million and a half movie-goers will become an important asset to our partners and the future of the movie industry.”

What We’re Seeing From The Stock As A Result

As investors, one of the first things that we learn is that the news causes movement in the market. In this particular case, the news surrounding Helios and Matheson proved to be overwhelmingly positive. As a result, we’re seeing an overwhelmingly positive reaction in the market. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:47), HMNY is trading at $7.49 per share after a gain of $0.57 per share (8.24%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on HMNY. In particular, we’re interested in watching the continued growth of MoviePass. We’re also interested in following the company’s plans with regard to opening up multiple lines of revenue through the service. For example, Helios and Matheson plans on selling data and advertising to the producers of movies, restaurants, and services like Uber and Lyft as it works to put together the ultimate movie night experience for its subscribers. While some may be downplaying the potential here, between the subscriber revenue, advertising revenue, and data sales, this could prove to be a massive win for HMNY and all involved. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 7802
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...